Plain-English translation of NCT07295262 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new surgical tool called ICG-Cisplatin self-assembled nanoprobes that use special near-infrared light to help surgeons see liver cancer tumors more clearly during surgery. Patients receive an injection of this medication through an artery before surgery, and then surgeons use an infrared imaging camera during the operation to precisely identify and remove the cancer.
Current liver cancer surgery relies on the surgeon's visual judgment and feel, which can sometimes miss small tumor areas or remove too much healthy liver. This trial exists to see whether the medication can make tumors glow under special light during surgery, helping surgeons be more accurate and remove cancer while preserving more healthy liver tissue.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the fluorescent medication through an artery a short time before your scheduled liver cancer surgery. During the surgery, your surgeon will use a special infrared imaging camera to see where the cancer glows and will remove it accordingly. You will undergo standard post-operative care and monitoring after the procedure.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China